Economic impact of the introduction of the ProC Global assay in the screening strategy of protein C pathway abnormalities in unselected patients with a history of venous thromboembolism.
Toulon
P
P
Adda
R
R
Perez
P
P
D001780:Blood Coagulation Tests / Q000191:economics / Q000592:standards; D005343:Fibrinolytic Agents / Q000494:pharmacology; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins; D010314:Partial Thromboplastin Time; D010455:Peptides / Q000494:pharmacology; D011486:Protein C / Q000187:drug effects / Q000378:metabolism*; D011933:Reagent Kits, Diagnostic / Q000191:economics / Q000592:standards*; D013923:Thromboembolism / Q000097:blood* / Q000175:diagnosis; D020246:Venous Thrombosis / Q000097:blood* / Q000175:diagnosis
D005343:Fibrinolytic Agents; D036341:Intercellular Signaling Peptides and Proteins; D010455:Peptides; D011486:Protein C; D011933:Reagent Kits, Diagnostic; C049647:snake venom protein C activator